Answers are grounded in this paper and cite their sources.
In this issue of Blood Cancer Discovery, Varano and colleagues uncover a substantial fraction of high-grade B-cell lymphoma with MYC and BCL2(-BCL6) translocations (so called "double-hit" lymphomas or high-grade B-cell lymphoma-double-hit-BCL2) that lack detectable expression of the B-cell receptor. MYC translocation in these cells is mediated by RAG enzymes, induced in response to silencing of the B-cell receptor in a precursor cell, a feature that renders them resistant to polatuzumab vedotin. See related article by Varano et al., p. 364.
No takes yet. Share an insight, caveat, or question.
Shevchenko et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: